Barclays
NVCR icon

Barclays’s NovoCure NVCR Stock Holding History

Barclays’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-30,000
Closed -$894K – 5457
2024
Q4 		$894K Buy
+30,000
New +$635K ﹤0.01% 3448
2024
Q2 		– Sell
-300,000
Closed -$4.69M – 5175
2024
Q1 		$4.69M Buy
+300,000
New +$4.41M ﹤0.01% 1902
2021
Q1 		– Sell
-24,900
Closed -$4.31M – 5043
2020
Q4 		$4.31M Hold
24,900
– – ﹤0.01% 1612
2020
Q3 		$2.77M Buy
24,900
+7,800
+46% +$624K ﹤0.01% 1836
2020
Q2 		$1.01M Hold
17,100
– – ﹤0.01% 2745
2020
Q1 		$1.15M Buy
+17,100
New +$1.35M ﹤0.01% 2812

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Barclays's NVCR Position: Q2 2026 in Review

Barclays reduced its NovoCure (NVCR) stake by 18% in Q2 2026, selling an estimated $821K and leaving 243,136 shares worth $3.68M. The position accounts for ﹤0.01% of the portfolio, ranked #2006.

Barclays first reported a position in NVCR in Q4 2015 and has held it in 43 quarters since. The position peaked at $42.2M in Q4 2019. 218 funds tracked by Wall St. Rank hold NVCR as of Q2 2026.

  • Barclays held 243,136 shares of NovoCure worth $3.68M as of Q2 2026.
  • Barclays sold 54,280 NovoCure shares in Q2 2026, an estimated $821K.
  • NovoCure made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #2006 holding.
  • Barclays first reported a position in NovoCure in Q4 2015 and has held it in 43 quarters since.
  • Barclays's NovoCure position peaked at $42.2M in Q4 2019.
  • 218 funds tracked by Wall St. Rank held NovoCure as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.